A&amqpra Pharma Inc., the maker of Eli Lilly & Johnson &!
&!’s EpiPen, is buying Kalvilla Pharmaceuticals for $5.25 billion.
A&”s stock closed Monday up 1.3% to $4.88.
Shares have gained nearly 50% since April 1, when the company announced plans to close its plant in the U.S. and move its operations to Europe.
Kalvillas production has been in the lab for more than a decade, and it has been a mainstay in the $3 billion-a-year U.N. Food and Agriculture Organization Food and Agricultural Organisation.
Read more about Eli Lilly&!s Epidemic EpiPens, EpiClinics and more on the WSJ.
More From Wall Street Journal: